A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

Inclusion Criteria: * Age: 18-70 years old * Histologically confirmed colorectal adenocarcinoma * Radiologically or pathologically confirmed diagnosis of colorectal liver metastasis * Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary team (MDT) * With no prior treatment for liver metastasis, including chemotherapy, operation, radiotherapy, transcatheter hepatic arterial chemoembolization (TACE) and targeted therapy * Without extra-hepatic metastasis confirmed by CT, MRI or PET/CT (if necessary) scanning * With adequate bone marrow function: platelets ≥ 90 x 109/L; white blood cells ≥ 3×109/L; absolute neutrophil count (ANC) ≥ 1.5 x 109/L Serum bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN * Patient has no ascites and with adequate blood coagulation function, albumin ≥ 35 g/L * Grade A level of Child-Push Liver Function * Creatinine ≤ 1× ULN, or Calculated Creatinine Clearance \>50ml/min （Cockcroft-Gault Equation） * ECOG performance status of 0-2 * Life expectancy ≥ 3 months * Not appropriate for anti-EGFR or any other targeted therapy (with KRAS mutation or could not afford it) * Patients have provided a signed Informed Consent Form * With good compliance Exclusion Criteria: * With any extra-hepatic metastasis and/or primary tumor recurrence * Severe arterial embolism or ascites * With hemorrhagic tendency or coagulation disorders * Hypertensive crisis or hypertensive encephalopathy * Severe and uncontrolled systemic complications such as…